During my recent cruise, I experienced unexpected seasickness despite usually not being affected on cruise ships. I learned several contributing factors that played a role in my discomfort.

Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration (FDA) approving a novel oral pill that helps prevent motion-induced vomiting – the first ...

Add Yahoo as a preferred source to see more of our stories on Google. The US Food and Drug Administration (FDA) has approved Vanda Pharmaceuticals’ Nereus (tradipitant) for the prevention of vomiting ...

Dec 30 (Reuters) - Vanda Pharmaceuticals (VNDA.O), opens new tab said on Tuesday its drug for the prevention of motion-induced vomiting was approved by the U.S. health regulator, becoming the first ...

Skipper/owner of First Light, Elizabeth Tucker Wendell Teodoro/Getty Images Before Elizabeth Tucker set sail in the Rolex Sydney Hobart Yacht Race as skipper of the event’s only all-women crew, she ...

What Is Nereus, And Why Does It Matter? Nereus (tradipitant) is a new prescription medicine approved by the FDA to help prevent nausea and vomiting caused by motion (motion sickness) in adults, such ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The cost of the approved drug ...

Vanda Pharmaceuticals has received FDA approval for Nereus (tradipitant), an oral NK-1 receptor antagonist developed to prevent motion-induced vomiting. The approval makes Nereus the first new ...

Vanda Pharmaceuticals (VNDA) added ~21% in the premarket on Wednesday after the U.S. FDA approved its motion sickness therapy Nereus (tradipitant), developed in partnership with Eli Lilly (LLY).

The FDA approved tradipitant (Nereus), an oral neurokinin-1 (NK-1) receptor antagonist, to prevent vomiting induced by motion in adults, Vanda Pharmaceuticals announced Tuesday. The approval marks the ...